Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
COSM 
Cosmos Health Inc. (COSM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/22/2025: COSM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -77.23% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/22/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 11.49M USD | Price to earnings Ratio - | 1Y Target Price 3 |
Price to earnings Ratio - | 1Y Target Price 3 | ||
Volume (30-day avg) 192046 | Beta 3.9 | 52 Weeks Range 0.28 - 1.58 | Updated Date 04/25/2025 |
52 Weeks Range 0.28 - 1.58 | Updated Date 04/25/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.17 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-04-17 | When - | Estimate - | Actual -0.4043 |
Profitability
Profit Margin -29.73% | Operating Margin (TTM) -60.99% |
Management Effectiveness
Return on Assets (TTM) -15.85% | Return on Equity (TTM) -53.43% |
Valuation
Trailing PE - | Forward PE 52.63 | Enterprise Value 22414696 | Price to Sales(TTM) 0.21 |
Enterprise Value 22414696 | Price to Sales(TTM) 0.21 | ||
Enterprise Value to Revenue 0.41 | Enterprise Value to EBITDA -1.6 | Shares Outstanding 27284700 | Shares Floating 17137017 |
Shares Outstanding 27284700 | Shares Floating 17137017 | ||
Percent Insiders 28.32 | Percent Institutions 5.94 |
Analyst Ratings
Rating 4 | Target Price 3 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Cosmos Health Inc.
Company Overview
History and Background
Cosmos Health Inc., formerly known as Cosmos Holdings Inc., is a global healthcare group focusing on pharmaceuticals, nutraceuticals, own label, and consumer healthcare products. The company was founded in 2009. It has expanded through acquisitions and partnerships, aiming to provide integrated healthcare solutions.
Core Business Areas
- Pharmaceuticals: Distribution and sales of generic and branded pharmaceutical products.
- Nutraceuticals: Development, manufacturing, and distribution of nutraceutical products and dietary supplements.
- Own Label Products: Developing and marketing own-label healthcare and wellness products.
- Consumer Healthcare Products: Sales of consumer healthcare products
Leadership and Structure
The leadership team includes Grigorios Siokas (CEO). The company has a board of directors and operates with various departments responsible for sales, marketing, operations, and finance.
Top Products and Market Share
Key Offerings
- Pharmaceuticals: Generic and branded pharmaceuticals distributed across various markets. Market share data varies by region and specific product. Competitors include major pharmaceutical distributors and generic drug manufacturers. Revenue and market share information from pharmaceuticals are not publicly separated in Cosmos Health filings.
- Nutraceuticals: Cosmos Health markets its nutraceutical products through its own brand and its distributors. The nutraceuticals market is highly competitive with many established players. Market share information is not publicly available. Competitors include brands like Nature's Bounty and GNC. Revenue and market share information from nutraceuticals are not publicly separated in Cosmos Health filings.
Market Dynamics
Industry Overview
The healthcare industry is experiencing growth due to an aging population, increased healthcare spending, and advancements in medical technology. The nutraceutical and pharmaceutical markets are particularly competitive.
Positioning
Cosmos Health Inc. aims to be a global player in the healthcare sector, focusing on distribution, branded products, and its own label offerings. They face competition from larger, more established companies.
Total Addressable Market (TAM)
The total addressable market for pharmaceuticals and nutraceuticals is in the hundreds of billions globally. Cosmos Health Inc. is positioned to capture a share of this market through strategic partnerships and product development.
Upturn SWOT Analysis
Strengths
- Global Presence
- Diverse Product Portfolio
- Strategic Partnerships
Weaknesses
- Limited Brand Recognition
- High Debt Levels
- Volatile Stock Performance
- Limited market share and financial resources compared to larger competitors.
Opportunities
- Expanding into New Markets
- Acquisitions of Complementary Businesses
- Increased Demand for Healthcare Products
Threats
- Intense Competition
- Regulatory Changes
- Economic Downturns
Competitors and Market Share
Key Competitors
- TEVA
- VRX
- PRGO
Competitive Landscape
Cosmos Health Inc. faces intense competition from larger, more established companies with greater resources and brand recognition. To compete effectively, Cosmos Health needs to leverage its strengths, address its weaknesses, and capitalize on opportunities in the market.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Cosmos Health Inc. has experienced growth through acquisitions and expansion into new markets.
Future Projections: Future growth projections are dependent on successful execution of strategic initiatives and market conditions. Analyst estimates should be sought.
Recent Initiatives: Recent initiatives likely include strategic acquisitions and partnerships.
Summary
Cosmos Health Inc. is a growing healthcare company with a global presence and diverse product portfolio, but it faces challenges due to limited brand recognition and a competitive market. Successful execution of its strategic initiatives and acquisitions is crucial for future growth. High debt levels and negative cash flow are significant concerns for the company. The company needs to focus on improving profitability and securing additional funding to sustain its operations and growth plans.
Similar Companies
PRGO
Perrigo Company PLC
PRGO
Perrigo Company PLC
TEVA
Teva Pharma Industries Ltd ADR
TEVA
Teva Pharma Industries Ltd ADR
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Financial News Sources
- Market Research Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investors should conduct their own research and consult with a financial advisor before making any investment decisions. Market share estimates are approximate and based on available data.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cosmos Health Inc.
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2012-10-11 | Chairman & CEO Mr. Grigorios Siokas | ||
Sector Healthcare | Industry Medical Distribution | Full time employees 149 | |
Full time employees 149 | |||
Cosmos Health Inc. manufactures, develops, and trades branded nutraceutical products in Greece, the United States, Croatia, Bulgaria, Ireland, the Cayman Islands, the UAE, the United Kingdom, and Cyprus. The company offers medicines, OTC medicines, nutraceutical products, vitamins, minerals, and dietary health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. It also provides ASTO-CHOL (Pravastatin), Diorium (Omeprazole), HEART-FREE (Clopidogrel), LIPICHOL (Atorvastatin), Miltus (Donepezil), Newzypra (Olanzapine), PNEUMO-KAST (Montelukast), Sahar (Pioglitazone), VIVALCID (Leucovorin), and Diabit-is (Sitagliptin). In addition, the company offers branded biocides and antiseptic soaps under the C-Sept and C-Scrub brand names. Other pharmaceutical products include Melatonin Spray, used to reduce insomnia and jet lag to promote peaceful sleep; Otikon ear drops, which is a Class II medical device in the form of ear drops; and Bio-bebe, an organic infant care and nutrition brand. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies, and independent specialty distributors. Cosmos Health Inc. was incorporated in 2009 and is headquartered in Chicago, Illinois.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.